Recall and failure to market Omontys was always a concern - read the old 10ks. The deaths were expected, hence the additional warning label from FDA, (read the trials) just that the voluntary recall made it tough since AFFY does not have an experienced staff to investigate or handle these situations (in 10K). Voluntary recall was a questionable move since FDA did not mandate the recall.
Now worst case scenario has happened and they are winding down the company. The drug will survive along with it's patents and royalties but the company may not, or will be part of something else.
If you can't afford to lose money, you should sell on the next bonuce and not trade again with money you can't afford to lose. If you can take the risk, like all stocks, go ahead and make your move.